News & Events Press Releases Read More Allyx Therapeutics Announces Successful Completion of Two Additional Studies of Lead Candidate ALX-001 December 10, 2025 Read More Neurology Live: Synapse-Targeting Agent ALX-001 Ready for Phase 2 Following Early-Stage ProgressNeurology Live: on First Patient Treated July 9, 2024 Read More U.S. Senator Chris Murphy Highlights New Haven’s Allyx Therapeutics As “Innovator Of The Month” April 4, 2024 Read More Allyx in NeurologyLive: Potential of mGluR5 Modifier ALX-001 in Neurodegenerative Disorders March 14, 2024 Read More Yale’s Adam Mecca, MD, PhD Discusses ALX-001 with NeurologyLive November 14, 2023 Read More Allyx sets Phase II plans for AD in motion after Phase Ia October 31, 2023 Read More NIA Small Business Showcase: Allyx Therapeutics, Inc. June 15, 2022 Read More Bristol Myers drug candidate repairs neuronal damage in Alzheimer’s mouse models Read More Allyx, BMS and Yale Announce License Agreement January 13, 2021 Read More Drug Restores Cells and Memories in Alzheimer’s Mouse Models July 5, 2017 Read More Yale Discovery Could Lead to Alzheimer’s Drug, Restored Memory September 3, 2013 Upcoming Presentations Check back soon for upcoming presentations…
